Equity Overview
Price & Market Data
Price: $2.38
Daily Change: +$0.03 / 1.26%
Daily Range: $2.31 - $2.48
Market Cap: $260,022,160
Daily Volume: 884,551
Performance Metrics
1 Week: -1.25%
1 Month: -14.44%
3 Months: 40.24%
6 Months: -35.95%
1 Year: -56.19%
YTD: -53.80%
Company Details
Employees: 100
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.